Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biovie Inc (BIVI)

Biovie Inc (BIVI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,199
  • Shares Outstanding, K 7,540
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,540 K
  • EBIT $ -19 M
  • EBITDA $ -19 M
  • 60-Month Beta 0.36
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.36

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.81
  • Number of Estimates 1
  • High Estimate -0.81
  • Low Estimate -0.81
  • Prior Year -4.60
  • Growth Rate Est. (year over year) +82.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1000 +9.09%
on 12/30/25
1.4600 -17.81%
on 12/22/25
-0.2100 (-14.89%)
since 12/19/25
3-Month
1.1000 +9.09%
on 12/30/25
1.9500 -38.46%
on 10/27/25
-0.7100 (-37.17%)
since 10/21/25
52-Week
1.1000 +9.09%
on 12/30/25
21.2000 -94.34%
on 01/22/25
-19.3000 (-94.15%)
since 01/21/25

Most Recent Stories

More News
New to The Street Broadcasts Show #716 Tonight at 6:30 PM ET on Bloomberg Television Featuring Stardust Power (NASDAQ:SDST), BioVie (NASDAQ:BIVI), Roadzen (NASDAQ:RDZN), with Special Segments from Kelsey Grammer on KAREN and Andrew Shaw of 250DAYS.ORG

The show airs as sponsored programming with national television commercials from Synergy CHC, NeOnc Technologies, The Sustainable Green Team (SGTM), Roadzen, and Aeries Technology (AERT)

RDZN : 1.8500 (+0.54%)
SDST : 4.02 (+2.03%)
BIVI : 1.2000 (-1.64%)
BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson’s Disease

- Patient-centric trial aiming to evaluate whether bezisterim can help delay disease progression reaches enrollment milestone - - Topline Results from the SUNRISE-PD Trial Expected in 1H 2026...

BIVI : 1.2000 (-1.64%)
HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

BIVI : 1.2000 (-1.64%)
New to The Street Broadcasts Tonight on Bloomberg at 6:30 PM EST Featuring Roadzen, BioVie, and TY J Young Wealth

Tonight's show is sponsored by commercials from Laser Photonics, DataVault, Aeries Technology, Sustainable Green Team, PetVivo, and Synergy CHC

RDZN : 1.8500 (+0.54%)
SNYR : 1.8400 (+1.66%)
LASE : 2.17 (+3.33%)
BIVI : 1.2000 (-1.64%)
AERT : 0.5999 (-0.18%)
DVLT : 0.7462 (+4.91%)
SGTM : 0.1020 (+2.00%)
Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on December 9

CARSON CITY, Nev., Nov. 19, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and...

BIVI : 1.2000 (-1.64%)
Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

BIVI : 1.2000 (-1.64%)
Nexalin Technology and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FLORIDA / ACCESS Newswire / October 17, 2025 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and BioVie, Inc. (Nasdaq:BIVI) on the RedChip Small Stocks, Big...

NXL : 0.6238 (-0.49%)
BIVI : 1.2000 (-1.64%)
BioVie to Host Live Investor Webinar and Q&A on Oct. 8

CARSON CITY, Nev., Sept. 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and...

BIVI : 1.2000 (-1.64%)
BioVie and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FLORIDA / ACCESS Newswire / September 26, 2025 / RedChip Companies will air interviews with BioVie Inc. (NASDAQ:BIVI) and FibroBiologics, Inc. (Nasdaq:FBLG) on the RedChip Small Stocks, Big Money™...

BIVI : 1.2000 (-1.64%)
FBLG : 0.3265 (+1.24%)
BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

CARSON CITY, Nev., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and...

BIVI : 1.2000 (-1.64%)

Business Summary

BioVie Inc. engages in developing drug therapies for liver disease. The company's product candidate includes BIV201, which are in clinical stage. BioVie Inc. is based in SANTA MONICA, CA.

See More

Key Turning Points

3rd Resistance Point 1.3133
2nd Resistance Point 1.2867
1st Resistance Point 1.2533
Last Price 1.2000
1st Support Level 1.1933
2nd Support Level 1.1667
3rd Support Level 1.1333

See More

52-Week High 21.2000
Fibonacci 61.8% 13.5218
Fibonacci 50% 11.1500
Fibonacci 38.2% 8.7782
Last Price 1.2000
52-Week Low 1.1000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar